AVIR

Atea Pharmaceuticals, Inc. [AVIR] Stock Forecast

Q: What is Atea Pharmaceuticals, Inc. stock symbol ?

Atea Pharmaceuticals, Inc. is a US stock, located in Boston of Ma and trading under the symbol AVIR

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

AVIR Stock Summary

AVIR has more than 3 years of cash runway (38 months)

EPS has been decreasing for the past 3 years (Yearly statements)

EPS has been decreasing for the past 3 quarters (Quarter statements)

Top 10 Correlated ETFs

AVIR

Top 10 Correlated Stocks

AVIR

In the News

AVIR Financial details

Company Rating

Neutral

Market Cap

316.46M

Income

-135.96M

Revenue

Book val./share

6.65

Cash/share

6.93

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

06 May 2024

P/E

-2.19

Forward P/E

PEG

-1.22

P/S

P/B

0.49

P/C

0.53

P/FCF

-3.46

Quick Ratio

31.5

Current Ratio

31.93

Debt / Equity

LT Debt / Equity

EPS (TTM)

-1.64

EPS next Y

EPS next Q

EPS this Y

17.27%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

17.5%

SMA20

SMA50

SMA100

33.33%

Inst Own

53.7%

Inst Trans

0.79%

ROA

-22%

ROE

-21%

ROC

-0.27%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

Shs Float

Target Price

52W Range

2.765-5.19

52W High

-26.3%

52W Low

+84.25%

RSI

Rel Volume

0.34

Avg Volume

437.29K

Volume

147.16K

Perf Week

-4.29%

Perf Month

-7.88%

Perf Quarter

19.64%

Perf Half Y

19.64%

Beta

0.162

Volatility

0.03%, 0.12%

Prev Close

-0.41%

Price

3.685

Change

-0.41%

AVIR Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0.59	4.24	0	0
Net income per share	-0.16	-0.13	1.46	-1.39	-1.63
Operating cash flow per share	-0.16	3.6	-1.05	-1.45	-1.02
Free cash flow per share	-0.16	3.6	-1.05	-1.48	-1.02
Cash per share	0.26	10.31	9.23	13.27	6.93
Book value per share	-0.6	6.65	8.57	7.69	6.66
Tangible book value per share	-0.6	6.65	8.57	7.69	6.66
Share holders equity per share	-0.6	6.65	8.57	7.69	6.66
Interest debt per share	0	0	0	0.17	0.03
Market cap	2.51B	3.44B	740.41M	400.41M	254.34M
Enterprise value	2.48B	2.59B	-23.77M	-243.17M	112.92M
P/E ratio	-186.23	-317.03	6.11	-3.45	-1.87
Price to sales ratio	0	70.82	2.11	0	0
POCF ratio	-195.61	11.61	-8.51	-3.31	-2.98
PFCF ratio	-195.58	11.61	-8.51	-3.26	-2.98
P/B Ratio	-50.57	6.29	1.04	0.63	0.46
PTB ratio	-50.57	6.29	1.04	0.63	0.46
EV to sales	0	53.34	-0.07	0	0
Enterprise value over EBITDA	-170.31	-235.59	-0.17	1.86	-0.69
EV to operating cash flow	-193.92	8.74	0.27	2.01	-1.32
EV to free cash flow	-193.89	8.74	0.27	1.98	-1.32
Earnings yield	-0.01	0	0.16	-0.29	-0.53
Free cash flow yield	-0.01	0.09	-0.12	-0.31	-0.34
Debt to equity	0	0	0	0	0
Debt to assets	-0.01	0	0	0	0
Net debt to EBITDA	1.48	77.21	-5.52	4.93	0.86
Current ratio	9	2.73	13.58	35.77	18.24
Interest coverage	0	0	0	-11.72	0
Income quality	0.91	-27.11	-0.72	1.04	0.63
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0.44	0.13	0	0
Research and developement to revenue	0	0.78	0.48	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0.02	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	-0.12	-1.37	-0.14	-7.47	0
Stock based compensation to revenue	0	0.15	0.11	0	0
Graham number	1.48	4.44	16.8	15.53	15.63
ROIC	0.28	-0.02	0.17	-0.2	-0.3
Return on tangible assets	-0.61	-0.01	0.16	-0.17	-0.23
Graham Net	-0.6	6.53	8.47	12.96	6.46
Working capital	19.48M	547.68M	715.52M	642.44M	558.08M
Tangible asset value	-49.57M	547.8M	710.08M	640.57M	555.19M
Net current asset value	-49.73M	547.65M	709.59M	634.79M	550.68M
Invested capital	0	0	0	0	0
Average receivables	0	2.91M	2.91M	0	0
Average payables	469.5K	304K	2.3M	3.54M	3.4M
Average inventory	0	0	0	0	0
Days sales outstanding	0	43.64	0	0	0
Days payables outstanding	11.77K	1.15K	57.07K	3.58K	3.73K
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	8.36	0	0	0
Payables turnover	0.03	0.32	0.01	0.1	0.1
Inventory turnover	0	0	0	0	0
ROE	0.27	-0.02	0.17	-0.18	-0.24
Capex per share	0	0	0	-0.02	0

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0	0
Net income per share	-0.41	-0.43	-0.34	-0.4	-0.47
Operating cash flow per share	-0.26	-0.36	-0.19	-0.21	-0.26
Free cash flow per share	-0.24	-0.36	-0.19	-0.21	-0.26
Cash per share	13.27	7.45	7.29	7.14	6.93
Book value per share	7.69	7.42	7.22	6.98	6.65
Tangible book value per share	7.69	7.42	7.22	6.98	6.65
Share holders equity per share	7.69	7.42	7.22	6.98	6.65
Interest debt per share	0.1	-0.04	0.03	0.03	0.03
Market cap	400.61M	279.16M	311.91M	250.2M	254.48M
Enterprise value	-242.97M	98.85M	100.98M	114.9M	113.06M
P/E ratio	-2.91	-1.97	-2.77	-1.89	-1.62
Price to sales ratio	0	0	0	0	0
POCF ratio	-18.59	-9.35	-19.35	-14.22	-11.66
PFCF ratio	-20.44	-9.35	-19.35	-14.22	-11.66
P/B Ratio	0.63	0.45	0.52	0.43	0.46
PTB ratio	0.63	0.45	0.52	0.43	0.46
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	6.09	-2.38	-2.87	-2.82	-2.43
EV to operating cash flow	11.28	-3.31	-6.26	-6.53	-5.18
EV to free cash flow	12.4	-3.31	-6.26	-6.53	-5.18
Earnings yield	-0.09	-0.13	-0.09	-0.13	-0.15
Free cash flow yield	-0.05	-0.11	-0.05	-0.07	-0.09
Debt to equity	0	0	0	0	0
Debt to assets	0	0	0	0	0
Net debt to EBITDA	16.13	4.34	6	3.33	3.04
Current ratio	35.77	51.16	38.42	31.93	18.24
Interest coverage	-7.14	6.49	0	0	0
Income quality	0.63	0.84	0.57	0.53	0.56
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	-0.09	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	18.68	0	0	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	8.46	8.43	7.41	7.9	8.38
ROIC	-0.06	-0.07	-0.06	-0.07	-0.08
Return on tangible assets	-0.05	-0.06	-0.05	-0.05	-0.07
Graham Net	12.95	7.21	7.01	6.82	6.45
Working capital	642.44M	620.03M	604.67M	584.42M	558.08M
Tangible asset value	640.57M	618.18M	602.35M	581.73M	555.19M
Net current asset value	634.79M	612.44M	597.15M	576.97M	550.68M
Invested capital	0	0	0	0	0
Average receivables	2.26M	0	0	0	0
Average payables	1.83M	1.63M	2.33M	2.18M	2.32M
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	2.21K	605.77	3.43K	341.83	3.68K
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0.04	0.15	0.03	0.26	0.02
Inventory turnover	0	0	0	0	0
ROE	-0.05	-0.06	-0.05	-0.06	-0.07
Capex per share	0.02	0	0	0	0

AVIR Frequently Asked Questions

What is Atea Pharmaceuticals, Inc. stock symbol ?

Atea Pharmaceuticals, Inc. is a US stock , located in Boston of Ma and trading under the symbol AVIR

What is Atea Pharmaceuticals, Inc. stock quote today ?

Atea Pharmaceuticals, Inc. stock price is $3.685 today.

Is Atea Pharmaceuticals, Inc. stock public?

Yes, Atea Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 437.29K
Market Capitalization 316.46M
Employee 75
CEO Dr. Jean-Pierre Sommadossi Ph.D.
Headquarters Boston,MA,US
IPO Date 2020-10-30
Website https://ateapharma.com

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.